May 15, 2020
How do medtech investors, CEOS manage portfolio companies going forward?
DeviceTalks Weekly: Ep. 10 – How do medtech investors, CEOS manage portfolio companies going forward?
In this week’s episode of DeviceTalks Weekly, we talk with two successful starters of medtech companies about how they’re building and maintaining their medtech portfolios during this pandemic landscape.
Our guests this week are…
• Justin Klein, MD, managing partner, Vensana Capital
• Duke Rohlen, chairman, Ajax Health
Together, Klein and Rohlen have created, backed and sold medtech companies that have generated billions.
Klein, formerly of New Enterprise Associates, now co-manages his own venture firm, Vensana Capital. He previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), EPIX Therapeutics (acquired), FIRE1, GPB Scientific, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Ve…